Search
SAR-260301
go.drugbank.com/drugs/DB33608InvestigationalCategories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitorsMizolastine
go.drugbank.com/drugs/DB12523ApprovedMizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).
RDEA806
go.drugbank.com/drugs/DB05228InvestigationalRDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.
Mephenytoin
go.drugbank.com/drugs/DB00532ApprovedWithdrawnMephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. … These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.
Besigomsin
go.drugbank.com/drugs/DB20894ExperimentalBesigomsin is a small molecule drug. Besigomsin has a monoisotopic molecular weight of 416.18 Da.
Categories: Compounds used in a research, industrial, or household settingINCB-9471
go.drugbank.com/drugs/DB12960InvestigationalINCB-9471 is a novel, orally available CCR5 antagonist that is part of a new class of drugs to treat HIV/AIDS. It is a potent, selective inhibitor of the HIV-1 virus.
PX-12
go.drugbank.com/drugs/DB05448Investigationaltumor growth in animal models. … Since high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced
DA-697b
go.drugbank.com/drugs/DB06001ExperimentalDA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.
FP-1096
go.drugbank.com/drugs/DB05310ExperimentalFP1096 reduced the painful symptoms of endometriosis in trial subjects with very minimal side effect.
KAND567
go.drugbank.com/drugs/DB16511InvestigationalBecause COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently being tested as a treatment for those with the illness[L32908].